scholarly journals VASCULAR ENDOTHELIAL GROWTH FACTOR IN CHILDREN WITH THALASSEMIA MAJOR PDF

2013 ◽  
Vol 5 (1) ◽  
pp. e2013044 ◽  
Author(s):  
Sameh Samir Fahmey ◽  
Hassan Naguib ◽  
Sanna Abdelshafy ◽  
Rasha Alashry
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Blood Transfusion ◽  
Elevated Serum ◽  
Thalassemia Major ◽  
Enzyme Linked Immunosorbent Assay ◽  
Vascular Endothelial ◽  
Healthy Controls ◽  
Endothelial Growth Factor ◽  
Vegf Level

Background: The β-Thalassemia syndromes are the most common hereditary chronic hemolytic anemia due to impaired globin chain synthesis.  Vascular endothelial growth factor (VEGF) plays several roles in angiogenesis which is a crucial process in the pathogenesis of several inflammatory, autoimmune and malignant diseases .Endothelial damage and inflammation make a significant contribution to the pathophysiology of β-thalassemia. Purpose: The aim of the study was to assess serum VEGF level in children with beta-thalassemia major as a marker of angiogenesis. Methods: Blood samples were collected from 40 patients with thalassemia major and 10 healthy controls and assayed for VEGF by enzyme-linked immunosorbent assay. Results: VEGF level was significantly higher in patients with β-Thalassemia major than healthy controls (p=0.001).In addition, VEGF level was higher in splenectomised thalassemic patients than non splenectomised ones (p=0.001) .However, there were a positive correlation between VEGF and chelation starting age (p=0.008) and a negative correlation between VEGF and frequency of blood transfusion (p=0.002). Conclusion: thalassemia patients, especially splenectomized, have elevated serum levels of VEGF. Early chelation and regular blood transfusion help to decrease serum VEGF and the risk of angiogenesis.  

Diagnostic Value of Video-Dermatoscopy in Patients with Systemic Sclerosis and Dermatomyositis with its relation to Serum Vascular Endothelial Growth Factor (S.VEGF)

QJM ◽  
2021 ◽  
Vol 114 (Supplement_1) ◽  
Author(s):  
Naglaa Fathy Salama Sayed ◽  
Hoda Ahmed Mounib ◽  
Rania Mahmoud Elhusseiny
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Systemic Sclerosis ◽  
Growth Factor ◽  
Connective Tissue ◽  
Connective Tissue Diseases ◽  
Enzyme Linked Immunosorbent Assay ◽  
Vascular Endothelial ◽  
Healthy Controls ◽  
Endothelial Growth Factor ◽  
Vegf Level

Abstract Background Systemic sclerosis and dermatomyositis are autoimmune connective tissue diseases affecting the skin and various internal organs. Systemic sclerosis is characterized by fibrotic arteriosclerosis of peripheral and visceral vasculature. Objective Analysis of video dermatoscopic picture of systemic sclerosis and dermatomyositis patients and find a characteristic feature for both. Assess serum vascular endothelial growth factor (VEGF) in these patients using enzyme linked immunosorbent assay (ELISA) kits. Perform a statistical analysis of the results to find a relation between video dermatoscopic Picture of systemic sclerosis and dermatomyositis patients and their serum VEGF to help in diagnosis, grading, prognosis and management. Patients and Methods Our case control study included 25 patients with SSc or DM (2555 years) recruited from Ain Shams University Hospitals and 25 apparent healthy controls with matched age and sex. After the study had been approved by Ain shams University of Medical Sciences Research Ethics Committee, all the subjects signed an informed consent before inclusion in the study. Results Serum VEGF level was highly significant in patients than in controls. This may be explained by the excessive release of VEGF in patients due to hypoxia caused by microvascular occlusion that not present in healthy controls. Conclusion Microvascular abnormalities are the earliest features of SSc and DM with elevation of serum VEGF level indicating its role in disease pathogenesis and disturbance of microvessls. Videodermoscopy and measurement of serum VEGF are effective tools in diagnosis, prognosis and grading of autoimmune connective tissue diseases as SSc and DM.

scholarly journals The prognostic value of vascular endothelial growth factor in patients with renal cell carcinoma: a systematic review of the literature and meta-analysis

2017 ◽  
Vol 40 (2) ◽  
pp. 40 ◽  
Author(s):  
Hongliang Shen ◽  
Qingjun Liu ◽  
Mingyi Li ◽  
Peiqian Yang
Keyword(s):  
Renal Cell Carcinoma ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Prognostic Value ◽  
Meta Analysis ◽  
Elevated Serum ◽  
Vascular Endothelial ◽  
Tumor Expression ◽  
Endothelial Growth Factor ◽  
Vegf Level

Objective: Vascular endothelial growth factor (VEGF) serum level or tumor expression may be prognostic in renal cell carcinoma (RCC). The purpose of this meta-analysis was to examine the prognostic value of serum VEGF level and tumor expression in patients with RCC. Methods: PubMed and EMBASE databases were searched until September 26, 2016. Prospective and retrospective studies of RCC patients that had VEGF levels measured were included. Outcome measures were overall survival (OS), disease-specific survival (DSS), and progression-free survival (PFS). Results: A total of 14 studies were included in the meta-analysis. In patients with RCC, elevated serum VEGF level was not associated with OS (pooled hazard ratio [HR] = 1.16; 95% confidence interval [CI]: 0.52 to 2.60; p = 0.716), but was associated with poor DSS (pooled HR = 4.22; 95% CI: 2.02 to 8.79; p < 0.001) and PFS (pooled HR = 1.50; 95% CI: 1.22 to 1.85; p < 0.001). Removal of one study, however, resulted in elevated serum level being associated with poorer OS. Tumor VEGF expression was not associated with OS (pooled HR = 1.48; 95% CI: 0.74 to 2.95; p = 0.263), but was associated with worse DSS (pooled HR = 1.83; 95% CI: 1.24 to 2.71; p = 0.003). Conclusion: In patients with RCC, elevated serum VEGF level is associated with worse OS, DSS, and PFS, while tumor expression is only associated with worse DSS. The number of studies, however, was limited and the results should be interpreted with caution.

scholarly journals Serum vascular endothelial growth factor concentration in dogs diagnosed with chronic superficial keratitis

2014 ◽  
Vol 62 (1) ◽  
pp. 22-32
Author(s):  
Ireneusz Balicki ◽  
Aleksandra Sobczyńska-Rak
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Elevated Serum ◽  
Test Group ◽  
Enzyme Linked Immunosorbent Assay ◽  
Control Group ◽  
Vascular Endothelial ◽  
Healthy Dogs ◽  
The Right ◽  
Endothelial Growth Factor

The objective of this study was to measure the vascular endothelial growth factor (VEGF) levels in dogs diagnosed with chronic superficial keratitis (CSK). The study was performed on 25 German shepherds (14 males and 11 females, aged between 3 and 11 years). The VEGF levels were determined in blood serum using commercially available enzyme-linked immunosorbent assay (ELISA; Quantikine Canine VEGF Immunoassay, R&D Systems). The test group of affected German shepherds was subdivided into two subgroups, based on the area of corneal neovascularisation. The first subgroup (9 patients) comprised dogs with neovascularisation observed in 1 to 2 quadrants of the right and left cornea, while the second subgroup (16 patients) comprised dogs with neovascularisation observed in 3 to 4 quadrants of the right and left cornea. The control group comprised 12 clinically healthy German shepherds (7 males and 5 females, aged between 3 and 9 years). The results were then statistically analysed by the Mann-Whitney test. The study indicated that the median serum VEGF concentration in healthy dogs was 14.9 pg/mL. The VEGF level observed in sick German shepherds was elevated (19.5 pg/mL) as compared to the values found in healthy dogs; however, a statistically significant increase in VEGF concentration, as compared to the values observed in healthy dogs, was only noted in the first subgroup, where the median VEGF concentration was 22.0 pg/mL. Elevated serum VEGF concentration was observed in German shepherds diagnosed with CSK. A statistically significant increase in VEGF levels was observed in dogs in the first stage of the disease, i.e. the early stage of neovascularisation.

Vascular Endothelial Growth Factor (VEGF) is Released from Platelets during Blood Clotting: Implications for Measurement of Circulating VEGF Levels in Clinical Disease

1998 ◽  
Vol 94 (4) ◽  
pp. 395-404 ◽  
Author(s):  
Nicholas J. A. Webb ◽  
Martyn J. Bottomley ◽  
Carolyn J. Watson ◽  
Paul E. C. Brenchley
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Elevated Serum ◽  
Potential Contribution ◽  
Vegf Receptor ◽  
Vascular Endothelial ◽  
Disease States ◽  
Endothelial Growth Factor ◽  
Vegf Release ◽  
Vegf Level

1. Dysregulated vascular endothelial growth factor (VEGF) expression has been reported in several pathological states based upon evidence of elevated serum VEGF levels. Using two immunoassays for VEGF, this study determines normal plasma and serum VEGF ranges, determines which are more likely to reflect circulating VEGF levels and investigates a potential contribution of VEGF from platelets to VEGF levels detected in serum. 2. The presence of soluble VEGF receptor, sflt-1, at a molar excess of 7:1 significantly reduced measured VEGF levels in both assays. Serum VEGF levels were higher than plasma levels in children [(mean ± S.E.M.) 306.1 ± 39.4 versus 107.4 ± 24.9 pg/ml, P < 0.0001] and adults (249.4 ± 46.4 versus 76.1 ± 10.7 pg/ml, P < 0.0001). Serum VEGF increased with clotting time (P = 0.0005 t0 compared with 2 h samples); plasma VEGF levels were not affected by time between sampling and centrifugation. 3. Calcium-induced clotting of platelet-rich but not platelet-poor plasma induced VEGF release with a proportional response between platelet count and VEGF level and isolated platelets released significant quantities of VEGF upon incubation with thrombin. Reverse transcriptase—PCR studies confirmed that platelets express VEGF121 and VEGF165 mRNA. 4. These data suggest that plasma is the preferred medium to measure VEGF levels; a significant and highly variable platelet-mediated secretion of VEGF during the clotting process invalidates the use of serum as an indicator of circulating VEGF levels in disease states.

scholarly journals Serum vascular endothelial growth factor is a biomolecular biomarker of severity of diabetic retinopathy

2019 ◽  
Vol 5 (1) ◽  
Author(s):  
Sukriti Ahuja ◽  
Sandeep Saxena ◽  
Levent Akduman ◽  
Carsten H. Meyer ◽  
Peter Kruzliak ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Diabetic Retinopathy ◽  
Growth Factor ◽  
Elevated Serum ◽  
Enzyme Linked Immunosorbent Assay ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
First Time

Abstract Background Elevated serum vascular endothelial growth factor (VEGF) levels are associated with diabetic retinopathy (DR). Serum VEGF levels correlate with vitreous levels. Neuroretinal changes occur even before the appearance of vascular signs in DR. Role of VEGF as a biomarker for DR has not been assessed. Serum VEGF as a biomarker for severity of DR, was evaluated for the first time. Methods Consecutive cases of type 2 diabetes mellitus [without DR, (no DR, n = 38); non-proliferative DR, (NPDR, n = 38); proliferative DR, (PDR, n = 40)] and healthy controls (n = 40) were included. Serum VEGF was measured using enzyme linked immunosorbent assay. Accuracy of VEGF as a biomarker for severity of retinopathy was measured using the area under the receiver operator characteristic (ROC) curve. Results Serum VEGF levels in controls, No DR, NPDR and PDR groups showed significant incremental trend from 138.96 ± 63.37 pg/ml (controls) to 457.18 ± 165.69 pg/ml (PDR) (F = 48.47; p < 0.001). Serum VEGF levels were observed to be significantly elevated even before DR had set in clinically. ROC for serum VEGF levels was significant in discriminating between the cases and the controls and had good accuracy in discerning between subjects with and without retinopathy. The area under curve (AUC ± SE) for discrimination was significant: (a) cases and controls (n = 156): AUC = 0.858 ± 0.029, p < 0.001; (b) DR (NPDR + PDR) and No DR (n = 116): AUC = 0.791 ± 0.044, p < 0.001; and (c) NPDR and PDR (n = 78): AUC = 0.761 ± 0.056, p < 0.001, with over 90% projected sensitivity and specificity at various cut off values. Conclusion Serum VEGF level is a simple, effective laboratory investigative test in predicting the onset of DR in eyes showing no evidence of DR and serves as a reliable biomolecular biomarker for severity of DR.

scholarly journals Change of Vascular Endothelial Growth Factor Levels following Vitrectomy in Eyes with Proliferative Diabetic Retinopathy

2019 ◽  
Vol 2019 ◽  
pp. 1-7 ◽  
Author(s):  
Hui-Jin Chen ◽  
Zhi-Zhong Ma ◽  
Ying Li ◽  
Chang-Guan Wang
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Diabetic Retinopathy ◽  
Growth Factor ◽  
Proliferative Diabetic Retinopathy ◽  
Vitreous Hemorrhage ◽  
Enzyme Linked Immunosorbent Assay ◽  
Vascular Endothelial ◽  
Endothelial Growth Factor ◽  
Vegf Level ◽  
Recurrent Vitreous Hemorrhage

Purpose. To study the change of concentrations of vascular endothelial growth factor (VEGF) in vitreous cavity after vitrectomy in eyes with proliferative diabetic retinopathy (PDR). Methods. In this retrospective study, intravitreal fluid samples were taken at baseline (beginning of the vitrectomy) and postoperatively (several days later after vitrectomy) at the time of prophylactic injection of bevacizumab in forty-eight eyes of forty-eight patients with PDR. Postvitrectomy fluid samples were divided into four groups according to the time interval between the vitrectomy and the injection (group 1, 3–5 days; group 2, 6–10 days; group 3, 11–15 days; group 4, 16–21 days; twelve eyes in each group). Postvitrectomy fluid sample was paired with baseline sample for each eye. VEGF concentrations in the samples were determined by enzyme-linked immunosorbent assay. Recurrent vitreous hemorrhage and neovascular glaucoma within six months postvitrectomy were also analyzed. Results. Overall, the intravitreal VEGF level after vitrectomy (median, 36.95 pg/ml; range, 3.2–1,299.4 pg/ml) was significantly less than the VEGF level at baseline (median, 704.5 pg/ml; range, 30.6–1,981.1 pg/ml). Postoperative and baseline VEGF levels were significantly correlated (r = 0.499, p<0.01). Both the absolute value of postoperative VEGF concentrations and the postop/baseline VEGF ratios declined with time and dramatically decreased in groups 3 and 4. In only two eyes, the postoperative VEGF level was even higher than the baseline VEGF level (postop/baseline VEGF ratio >1), and recurrent vitreous hemorrhage developed within six months in these two eyes. Conclusions. After vitrectomy for PDR, intravitreal VEGF levels decreased substantially in the majority of patients, while persistent high-VEGF level occurred in a few individuals. Postoperative VEGF levels and postop/baseline VEGF ratio declined with time. The postop/preop VEGF ratio may serve as a predictor for late complications.

scholarly journals Female sexual dysfunction in systemic sclerosis: The role of endothelial growth factor and endostatin

2018 ◽  
Vol 4 (1) ◽  
pp. 71-76 ◽  
Author(s):  
Antonietta Gigante ◽  
Luca Navarini ◽  
Domenico Margiotta ◽  
Biagio Barbano ◽  
Antonella Afeltra ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Blood Flow ◽  
Systemic Sclerosis ◽  
Growth Factor ◽  
Sexual Dysfunction ◽  
Resistive Index ◽  
Serum Levels ◽  
Vascular Endothelial ◽  
Healthy Controls ◽  
Endothelial Growth Factor

Introduction: Since female sexual dysfunction in systemic sclerosis women is multifactorial, we can assume that vascular damage may play a role in pathogenesis. The aim of the study was to evaluate the clitoral blood flow, by Echo color Doppler, and to correlate it whit serum levels of vascular endothelial growth factor and endostatin. Methods: A total of 15 systemic sclerosis women and 10 healthy controls matched for sex and age were enrolled in this study. Serum VEGF165 and endostatin levels were determined in systemic sclerosis patients by commercial enzyme-linked immunosorbent assay kit. Clitoral blood flow was measured by Doppler indices of clitoral artery: pulsatile index, resistive index, and systolic/diastolic ratio were measured. Sexual dysfunction was assessed by Female Sexual Function Index. Results: Vascular endothelial growth factor (pg/mL) and endostatin (ng/mL) median values were significantly higher in systemic sclerosis women than healthy controls. Resistive index and systolic/diastolic ratio median values were significantly higher in systemic sclerosis women than healthy controls. Negative correlation exists between serum levels of vascular endothelial growth factor and resistive index (r = −0.55, p < 0.05). Positive correlation was observed between serum levels of endostatin and resistive index (r = 0.70, p < 0.01) and systolic/diastolic ratio (r = 0.77, p < 0.01). Discussion: We can suppose that clitoral blood flow in systemic sclerosis women is reduced not only for macro- and microvascular damage but also for impaired angiogenesis.

Preoperative Vascular Endothelial Growth Factor Levels as a Prognostic Marker for Stage II or III Colorectal Cancer Patients

2011 ◽  
Vol 4 ◽  
pp. CGM.S7113 ◽  
Author(s):  
Ozgur Kemik ◽  
Ahu Sarbay Kemik ◽  
Aziz Sümer ◽  
Sevim Purisa ◽  
A. Cumhur Dulger ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Cancer Patients ◽  
Elevated Serum ◽  
Stage Ii ◽  
Vascular Endothelial ◽  
Poor Survival ◽  
Colorectal Cancer Patients ◽  
Endothelial Growth Factor

Background The aim of the present study was to determine whether serum vascular endothelial growth factor (VEGF) can provide prognostic information independent of carcinoembryonic antigen levels in patients undergoing curative surgery. Methods Serum samples were collected from 158 patients with colorectal cancer and from 100 controls. Serum and tissue levels of VEGF were measured by enzyme-linked immunosorbent assay. Serum VEGF levels in colorectal cancer patients were compared with those in healthy controls, and we retrospectively assessed the association between serum VEGF levels and clinicopathologic findings and survival. Results VEGF expression was significantly higher in colorectal cancer tissue compared with nontumor tissue. Mean serum VEGF levels in patients were significantly higher than those in controls, and significantly higher in patients with large tumors, lymph node involvement, and distant metastases. Conclusion Elevated serum VEGF was significantly associated with poor survival, but was only an independent risk factor for poor survival in Stage II and/or III disease. Elevated serum VEGF is significantly associated with development of colorectal cancer, and lymph or distant invasive phenotypes and survival, especially in Stage II and III patients.

scholarly journals A novel mutation in the conserved sequence of vascular endothelial growth factor receptor 3 leads to primary lymphoedema

2018 ◽  
Vol 46 (8) ◽  
pp. 3162-3171 ◽  
Author(s):  
Ting Dai ◽  
Bohan Li ◽  
Bo He ◽  
Liwei Yan ◽  
Liqiang Gu ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Novel Mutation ◽  
Family Members ◽  
Growth Factor Receptor ◽  
Chinese Family ◽  
Vascular Endothelial ◽  
Healthy Controls ◽  
Endothelial Growth Factor ◽  
Congenital Lymphoedema

Objective To investigate whether lymphoedema in a Chinese family showed the hereditary and clinical characteristics of Milroy disease, an autosomal dominant form of congenital lymphoedema, typically characterized by chronic lower limb tissue swelling due to abnormal lymphatic vasculature development, and to perform mutational analyses of vascular endothelial growth factor receptor ( VEGFR)3. Methods Individuals from a three-generation family affected by congenital lymphoedema were clinically assessed for Milroy disease. Mutation analysis of VEGFR3 was performed using DNA from family members and healthy controls. Results Out of 20 family members, eight were diagnosed with hereditary lymphoedema. Mutation analyses revealed a novel mutation site for c.3163 G>A, resulting in a p.1055D>N mutation in the second tyrosine kinase domain of VEGFR3, which was present in affected individuals only (absent in all unaffected family members and 130 healthy controls). Computed functional analyses showed the mutation may lead to structural alterations with a probability of 0.99999 of being disease causing. Conclusion A novel mutation associated with Milroy disease was identified in a Chinese family, expanding our knowledge of VEGFR3 gene function and providing a potential molecular target for treating hereditary lymphoedema.

Sign in / Sign up

Export Citation Format

Share Document